Evidence map›Paper›PMID 25576331›Full record

ArticleWiener klinische Wochenschrift2015

Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?

Emrah Posul, Bulent Yilmaz, Gulali Aktas, Mevlut Kurt

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emrah PosulFaculty of Medicine, Department of Gastroenterology, Abant Izzet Baysal University, Golkoy, 14280, Bolu, Turkey.
Bulent Yilmaz
Gulali Aktas
Mevlut Kurt

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory markers have been studied in ulcerative colitis (UC) for diagnosis, disease activity, and prediction of relapse. Blood neutrophil-to-lymphocyte (N/L) ratio has been used to determine outcomes of some malignancies and coronary artery disease. Blood N/L ratio is a simple sign of clinical inflammation. In this study, we examined N/L ratio in recurrent patients suffering from UC.

methodsThe aim of the present study was to analyze N/L ratios in serum samples of UC patients in remission and active phases. Patients' age, extend of the disease, disease duration, disease activity, drug, and other medical history were all noted for patients. C-reactive protein, erythrocyte sedimentation rate, and complete blood count were determined for patients.

resultsForty-nine UC patients were admitted into the present study. The blood N/L ratios were significantly increased in active phase compared with inactive UC patients (p < 0.05). The cut-off value for N/L ratio for the detection of active UC patients was calculated as ≥ 2.3 using receiver operating characteristic analysis [sensitivity: 61.2 %, specificity: 66.7 %, AUC: 0.650 (0.540-0.760), p = 0.01].

conclusionsPresent study shows that in patients with UC, the blood N/L ratio is associated with active disease. N/L ratio may be used as an activity parameter in UC.

Indexed as

AdultAgedBiomarkersBlood Cell CountColitis, UlcerativeFemaleHumansLeukocyte CountLymphocytesMaleMiddle AgedNeutrophilsReproducibility of ResultsSensitivity and SpecificitySeverity of Illness IndexYoung AdultBiomarkers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.